At embecta (formerly part of BD), we are singularly focused on improving the lives of people living with diabetes. With a 100-year legacy of developing and providing solutions to the diabetes community, today, we are a global medical technology company and leader in insulin delivery devices. More than 30 million people in over 100 countries rely on our pen needle and syringe products every day. BD is the manufacturer of the advertised products. Privacy Policy: https://www.embecta.com/en-us/about/policies/privacy-policy-statement
| Website | https://www.embecta.com/ |
| Revenue | $1.1 billion |
| Employees | 1,127 (914 on RocketReach) |
| Founded | 2022 |
| Industry | Medical Devices |
| Keywords | Diabetes Care, Diabetes Management, Diabetes Treatment, Diabetes Technology, Diabetes Solutions, Insulin Delivery, Diabetes Supplies, Diabetes Prevention, Glucose Monitoring, Insulin Pumps, Diabetes Testing, Medical Devices, Blood Glucose Meters, Medical Technology, Patient Care, Endocrine Care, Healthcare Technology, Health Monitoring, Remote Patient Monitoring |
| Competitors | Roche, The Janssen Pharmaceutical Companies of Johnson & Johnson, BD, Novo Nordisk, Medtronic, Abbott, Ypsomed AG, Dexcom, LifeScan, Insulet Corporation +29 more (view full list) |
Looking for a particular embecta employee's phone or email?
The embecta annual revenue was $1.1 billion in 2026.
Devdatt Kurdikar is the President and Chief Executive Officer of embecta.
914 people are employed at embecta.